AwesomeCapital
Monday, June 24, 2019
Minerva Neurosciences (NERV): Jefferies maintains Buy, $18 target
Jefferies analyst Biren Amin: Clean safety profile suggests better than Zolpidem and Suvorexa
https://www.streetinsider.com/Analyst+Comments/Minerva+Neurosciences+%28NERV%29%2C+Jefferies+Says+Clean+Safety+Profile+Suggests+Its+Better+Than+Zolpidem+And+Suvorexant/15640102.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.
‹
›
Home
View web version
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.